How the molecular informations infl uence the therapeutic strategy against colorectal cancer?

Axel Grothey
Mayo Clinic College of Medicine, Department of Oncology, Rochester, USA

Colorectal cancer is not a homogenous disease, but it has different subgroups based on their molecular characteristics. NCCN and ESMO guidelines emphasize the importance of the determination of RAS and BRAF mutations in those patients who are intended to treat with targeted therapy. The increase in knowledge on the molecular changes will help to design and start a new generation of clinical trials, which will be designed not on their randomization of large groups of unselected patients, but rather on the consideration of the molecular subgroups determined before introducing therapy.

Kapcsolódó cikkek